Merck Enters Strategic Collaborations with Amgen, Incyte and Pfizer to Evaluate Novel Combination Anti-cancer Regimens with MK-3475
Dateline City:
WHITEHOUSE STATION, N.J.
Merck Also to Initiate Phase I “Signal Finding” Study with MK-3475 in 20 New Cancer Types
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
announced today it has signed three separate clinical collaboration
agreements, through subsidiaries, with Amgen Inc., Incyte Corporation
and Pfizer Inc. to evaluate novel combination regimens with MK-3475,
Merck’s investigational anti-PD-1 immunotherapy. The financial terms of
the agreements were not disclosed.
Language:
English
Contact:
MerckMedia:Ian McConnell, 908-423-3046orClaire Mulhearn, 908-423-7425orInvestors:Carol Ferguson, 908-423-4465orJustin Holko, 908-423-5088
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more
Source: Merck.com - Research and Development News - Category: Pharmaceuticals Tags: Oncology Newsroom Research and Development News Corporate News Latest News Source Type: news